https://orcid.org/0000-0002-2633-985X
Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Adam Reich, Catherine Reed, Christopher Schuster, Camille Robert, Tamas Treuer & Ennio Lubrano. (2023) Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021. Journal of Dermatological Treatment 34:1.
Read now
Read now
Paolo Dapavo, Niccolò Siliquini, Luca Mastorino, Gianluca Avallone, Martina Merli, Andrea Agostini, Caterina Cariti, Riccardo Viola, Elena Stroppiana, Anna Verrone, Michela Ortoncelli, Pietro Quaglino & Simone Ribero. (2022) Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. Journal of Dermatological Treatment 33:4, pages 2352-2357.
Read now
Read now
Craig Leonardi, Rei Tao, Solmaz Setayeshgar, Sisi Wang, Russel Burge, Baojin Zhu & William N. Malatestinic. (2022) Psoriasis treatment patterns and outcomes with ixekizumab in a real-world setting: results from a single US dermatology referral practice. Journal of Dermatological Treatment 33:4, pages 2278-2284.
Read now
Read now
Articles from other publishers (17)
Wayne Gulliver, Melinda J. Gooderham, Baojin Zhu, Christian Jossart, Sonia Montmayeur, Russel Burge & Catherine Reed. (2022) Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program. Dermatology and Therapy 13:1, pages 235-244.
Crossref
Crossref
Yayoi Tada, Hyunchung Kim, Dionysis Spanopoulos, Katsuyoshi Habiro, Katsuki Tsuritani, Yoshiyuki Yamada, Amartya Mandal, Yichen Zhong & Yusuke Hikichi. (2022) Treatment patterns, healthcare resource utilization, and costs in patients with moderate‐to‐severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study. The Journal of Dermatology 49:11, pages 1106-1117.
Crossref
Crossref
Matteo Megna, Luca Potestio, Elisa Camela, Gabriella Fabbrocini & Angelo Ruggiero. (2022) Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting. Dermatologic Therapy 35:9.
Crossref
Crossref
Wen Wang, Mei Liu, Jiayue Xu, Ling Li, Jing Tan, Jeff Jianfei Guo, Kevin Lu, Guowei Li & Xin Sun. (2022) Impact of time-varying exposure on estimated effects in observational studies using routinely collected data: protocol for a cross-sectional study. BMJ Open 12:7, pages e062572.
Crossref
Crossref
Craig Leonardi, Baojin Zhu, William N. Malatestinic, William J. Eastman, Jiaying Guo, Mwangi J. Murage, Casey Kar-Chan Choong, Russel Burge & Andrew Blauvelt. (2022) Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan® Databases. Advances in Therapy 39:7, pages 3214-3224.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Agata Janowska, Valentina Dini, Marco Romanelli, Vincenzo Calderone & Ersilia Lucenteforte. (2022) Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. Journal of Clinical Medicine 11:6, pages 1506.
Crossref
Crossref
Timothy Fitzgerald, Aimee M. Near, Hyunchung Kim, Amanda Teeple, Mobolaji Olurinde & Katelyn Rowland. (2022) Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database. Dermatology and Therapy 12:3, pages 741-752.
Crossref
Crossref
Andrew Blauvelt, Russel Burge, Gaia Gallo, Bridget Charbonneau, William Malatestinic, Baojin Zhu, Fangyu Wan & Benjamin Lockshin. (2022) A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab. Dermatology and Therapy 12:3, pages 701-714.
Crossref
Crossref
Mwangi J MurageNicole PrincicJulie ParkWilliam N MalatestinicBaojin ZhuBilal AtiyaScott A KernKeri B StengerAubrey Trevelin SpraberyAlexis Ogdie. (2022) Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. Journal of Managed Care & Specialty Pharmacy 28:2, pages 206-217.
Crossref
Crossref
Chang Xu, Amanda Teeple, Bingcao Wu, Timothy Fitzgerald & Steven R. Feldman. (2022) Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population. Dermatology 238:3, pages 438-447.
Crossref
Crossref
Marcus Schmitt-Egenolf, Jonatan Freilich, Natalia M. Stelmaszuk-Zadykowicz, Eydna Apol, Jes B. Hansen & Lars-Åke Levin. (2021) Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. Dermatology and Therapy 11:6, pages 2107-2121.
Crossref
Crossref
Mwangi J. Murage, Nicole Princic, Julie Park, William Malatestinic, Baojin Zhu, Bilal Atiya, Scott A. Kern, Keri B. Stenger, Aubrey Trevelin Sprabery & Alexis Ogdie. (2021) Real‐World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study. ACR Open Rheumatology 3:12, pages 879-887.
Crossref
Crossref
Federico Pirro, Giacomo Caldarola, Andrea Chiricozzi, Martina Burlando, Marco Mariani, Aurora Parodi, Ketty Peris & Clara De Simone. (2021) Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. Clinical Drug Investigation 41:10, pages 917-925.
Crossref
Crossref
D. Rosmarin, S. Smith, D. Shrom, R. Burge, K. See, M. McKean‐Matthews, T. Ridenour, C.‐Y. Lin & J. Gorelick. (2021) Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial. Skin Health and Disease 1:3.
Crossref
Crossref
Benjamin Lockshin, Angel Cronin, Ryan W. Harrison, Robert R. McLean, Laura Anatale‐Tardiff, Russel Burge, Baojin Zhu, William N. Malatestinic, Bilal Atiya, Mwangi J. Murage, Gaia Gallo, Bruce Strober & Abby Van Voorhees. (2021) Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 34:2.
Crossref
Crossref
Aaminah Azhar, Marcus Zaayman, Annika Silfvast‐Kaiser, Dario Kivelevitch, Alan Menter & So Yeon Paek. (2020) Ixekizumab in the treatment of moderate‐to‐severe plaque psoriasis: Patient adherence, satisfaction, and preferences. Dermatologic Therapy 34:1.
Crossref
Crossref
Sara Galimberti, Chiara Baldini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi, Francesco Ferro, Gabriele Buda, Edoardo Benedetti, Rita Fazzi, Laura Baglietto, Ersilia Lucenteforte, Antonello Di Paolo & Mario Petrini. (2020) The CoV-2 outbreak: how hematologists could help to fight Covid-19. Pharmacological Research 157, pages 104866.
Crossref
Crossref